These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32236928)

  • 1. [Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
    Jakubczyc A; Neurohr C
    Dtsch Med Wochenschr; 2020 Apr; 145(7):470-473. PubMed ID: 32236928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
    Higuero Sevilla JP; Memon A; Hinchcliff M
    Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment paradigms for connective tissue disease-associated interstitial lung disease.
    Kouranos V; Miranda G; Corte TJ; Renzoni EA
    Curr Opin Pulm Med; 2018 Sep; 24(5):453-460. PubMed ID: 30020142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
    Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
    Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspective of progressive-fibrosing interstitial lung disease.
    Kishaba T
    Respir Investig; 2022 Jul; 60(4):503-509. PubMed ID: 35431170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
    Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
    Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of interstitial lung disease associated with connective tissue disease.
    Mathai SC; Danoff SK
    BMJ; 2016 Feb; 352():h6819. PubMed ID: 26912511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
    de Lauretis A; Veeraraghavan S; Renzoni E
    Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease.
    Mulcaire-Jones E; Pugashetti JV; Oldham JM; Khanna D
    Semin Respir Crit Care Med; 2024 Jun; 45(3):435-448. PubMed ID: 38740369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of the Connective Tissue Disease-Related Interstitial Lung Diseases: A Narrative Review.
    Gao Y; Moua T
    Mayo Clin Proc; 2020 Mar; 95(3):554-573. PubMed ID: 32138882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of systemic sclerosis-associated interstitial lung disease.
    Roofeh D; Jaafar S; Vummidi D; Khanna D
    Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
    Chartrand S; Swigris JJ; Peykova L; Fischer A
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Connective Tissue Disease-Associated Interstitial Lung Disease.
    Kawano-Dourado L; Lee JS
    Clin Chest Med; 2021 Jun; 42(2):295-310. PubMed ID: 34024405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).
    Jee AS; Corte TJ
    Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
    Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
    Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in connective tissue disease-associated interstitial lung disease.
    Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
    Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lung involvement in rheumatic diseases].
    Bastian H; Krause A
    Dtsch Med Wochenschr; 2021 Jun; 146(11):752-756. PubMed ID: 34062592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.